The TP53-activated E3 ligase RNF144B is a tumour suppressor that prevents genomic instability

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53 is a critical tumor suppressor gene frequently mutated in human cancers.
• RNF144B, an E3 ubiquitin ligase, has demonstrated tumor suppressor activity but its precise role and targets remain largely unknown.
• This study investigates RNF144B's function in human cancers beyond the hematopoietic system.

Purpose of the Study:

• To elucidate the tumor suppressive role of RNF144B in human cancers.
• To identify RNF144B's molecular targets and mechanisms of action.
• To assess the clinical relevance of RNF144B in cancer development and patient prognosis.

Main Methods:

• Generated RNF144B-deficient cell models (human and mouse, normal and cancerous).
• Utilized proteomics, transcriptomics, in vitro/in vivo functional assays (proliferation, DNA repair, cell cycle, mitosis).
• Analyzed clinical datasets and performed bioinformatics analysis.

Main Results:

• RNF144B deficiency enhances cellular proliferation and transformation, particularly in lung adenocarcinoma.
• RNF144B regulates protein degradation involved in cell cycle, DNA damage response, and genomic stability.
• RNF144B loss correlates with chromosomal instability, mitotic defects, aneuploidy, and poor prognosis in human tumors.
• RNF144B-deficient lung cancer cells show resistance to specific chemotherapies.

Conclusions:

• RNF144B is a crucial tumor suppressor that maintains genomic stability.
• RNF144B's function is vital for preventing cancer development and progression.
• Clinical data supports RNF144B's role in tumor suppression and patient outcomes.